Evidence map›Paper›PMID 32789471›Full record

ArticleBioscience reports2020

Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.

Kaifei Zhao, Lin Xu, Feng Li, Jin Ao, Guojun Jiang, Rongshu Shi, Fang Chen, Qing Luo

Abstract readValidation Study
In one paragraph

Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Ariadne's Thread in the Network of Hepatocellular Carcinoma Immunobiology.Journal of clinical and translational hepatology · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kaifei ZhaoDepartment of Intervention, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.
Lin XuDepartment of Rehabilitation Medicine, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.
Feng LiDepartment of Intervention, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.
Jin AoDepartment of Intervention, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.
Guojun JiangDepartment of Intervention, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.
Rongshu ShiDepartment of Intervention, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.
Fang ChenDepartments of Cancer Research Laboratory, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.
Qing LuoDepartments of Cancer Research Laboratory, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to the heterogeneity of hepatocellular carcinoma (HCC), hepatocelluarin-associated differentially expressed genes were analyzed by bioinformatics methods to screen the molecular markers for HCC prognosis and potential molecular targets for immunotherapy.

methodsRNA-seq data and clinical follow-up data of HCC were downloaded from The Cancer Genome Atlas (TCGA) database. Multivariate Cox analysis and Lasso regression were used to identify robust immunity-related genes. Finally, a risk prognosis model of immune gene pairs was established and verified by clinical features, test set and Gene Expression Omnibus (GEO) external validation set.

resultsA total of 536 immune-related gene (IRGs) were significantly associated with the prognosis of patients with HCC. Ten robust IRGs were finally obtained and a prognostic risk prediction model was constructed by feature selection of Lasso. The risk score of each sample is calculated based on the risk model and is divided into high risk group (Risk-H) and low risk group (Risk-L). Risk models enable risk stratification of samples in training sets, test sets, external validation sets, staging and subtypes. The area under the curve (AUC) in the training set and the test set were all >0.67, and there were significant overall suvival (OS) differences between the Risk-H and Risk-L samples. Compared with the published four models, the traditional clinical features of Grade, Stage and Gender, the model performed better on the risk prediction of HCC prognosis.

conclusionThe present study constructed 10-gene signature as a novel prognostic marker for predicting survival in patients with HCC.

Indexed as

Gene Expression ProfilingNomogramsTranscriptomeAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, HepatocellularChildChild, PreschoolDatabases, GeneticFemaleHumansInfantInfant, NewbornBiomarkers, Tumor10-gene signaturebioinformaticsHepatocellular Carcinomaimmune related genesTCGA

Identifiers

PMID32789471
PMCPMC7457228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.